ZURICH, July 19 (Reuters) - Roche's Japanese subsidiary Chugai said on Tuesday subcutaneous injection of its Actemra drug has shown efficacy in rheumatoid arthritis compared to intravenous infusion.
Actemra (tocilizumab) is a prescription drug that’s used for arthritis and other conditions. The drug is given as an injection under the skin or an intravenous (IV) infusion. Actemra’s dosage depends ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra ...
The US Food and Drug Administration (FDA) has approved the biosimilar tocilizumab-aazg (Tyenne), Fresenius Kabi, the drug's manufacturer, announced today. This is the second tocilizumab biosimilar ...
Tocilizumab is effective and safe for rheumatoid arthritis, with long-term studies supporting its use and comparable cardiovascular risk to tumor necrosis factor inhibitors. Real-world data indicate ...
Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment “Biosimilars continue to be a key growth driver for Organon, and this acquisition complements ...
Actemra (tocilizumab) is a prescription drug that’s used to treat arthritis and other conditions. Actemra’s cost may depend on factors such as your dosage, whether you have health insurance, and the ...
Subcutaneous tocilizumab, alone or with methotrexate, showed superior efficacy over methotrexate monotherapy in treating rheumatoid arthritis in Chinese patients. The trial demonstrated higher ACR20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results